14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
PVLA vs IRON: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
IRON Wins Head-to-Head Institutional Verdict (3–1 across 6 Pillars · 3–2 Matrix Metrics)
IRON Overall Winner
6-Pillar Tally: PVLA 1 – 3 IRON (2 Tie)
Matrix Metrics: PVLA 2 – 3 IRON
As of Nov 16, 2026, Disc Medicine, Inc. (IRON) is the stronger overall head-to-head candidate over Palvella Therapeutics, Inc. (PVLA) in the Tradestie Institutional Equity Comparison Engine, winning 3–2 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). PVLA carries a Unified Composite Score of 48.2/100 (HOLD) at $145.03 (N/M Forward P/E, 0.0% operating margin), whereas IRON carries 46.6/100 (HOLD) at $77.72 (N/M Forward P/E, 0.0% operating margin).
Composite vs. Pillar Nuance: While PVLA currently prints a higher short-term Unified Composite Score (48.2/100 HOLD vs. IRON 46.6/100 HOLD), IRON captures the overall institutional head-to-head verdict (3–2 matrix metrics and 3–1 across the 6 pillars) due to superior fundamental profitability (0.0% vs. 0.0% operating margin) and revenue trajectory (+0.0% vs. +0.0% YoY).
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on PVLA vs IRON. Trailing 12-month operating profitability (PVLA 0.0% vs IRON 0.0%) and valuation multiples (PVLA N/M vs IRON N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $2.2B market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
IRON Moat ProfileCyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $3.8B market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ PVLA vs IRON Key Questions & Quantitative Answers
As of Nov 16, 2026, Disc Medicine, Inc. (IRON) is the stronger overall head-to-head candidate over Palvella Therapeutics, Inc. (PVLA) in the Tradestie Institutional Equity Comparison Engine, winning 3–2 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). PVLA carries a Unified Composite Score of 48.2/100 (HOLD) at $145.03 (N/M Forward P/E, 0.0% operating margin), whereas IRON carries 46.6/100 (HOLD) at $77.72 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While PVLA currently prints a higher short-term Unified Composite Score (48.2/100 HOLD vs. IRON 46.6/100 HOLD), IRON captures the overall institutional head-to-head verdict (3–2 matrix metrics and 3–1 across the 6 pillars) due to superior fundamental profitability (0.0% vs. 0.0% operating margin) and revenue trajectory (+0.0% vs. +0.0% YoY).
IRON leads the Growth & Scale pillar: PVLA posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with IRON at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, PVLA generates N/A in USD-normalized revenue versus N/A for IRON. In operating R&D and SG&A reinvestment, PVLA deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for IRON.
PVLA and IRON trade at balanced relative valuation multiples. PVLA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas IRON trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against PVLA (-63.4% ROE) versus IRON (-41.3% ROE) capital efficiency.
In options market volatility and institutional positioning, PVLA carries 47.9% implied volatility (2nd %ile, Compressed (<25th %ile)), a 3.82x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.66β · 75% Vol realized risk). By comparison, IRON carries 46.1% implied volatility (3rd %ile, Compressed (<25th %ile)), a 0.71x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a SURGE options structure phase (1.21β · 51% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.